Charles River Laboratories International, Inc. announced the launch of their new CliniPrimeTM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials. CliniPrime products provide rapid access to starting materials for cell, and gene-modified cell therapies with a standardized production process for high-quality GMP-compliant products. All CliniPrime products meet the essential regulatory guidelines for clinical trial development and the commercial manufacturing of advanced therapies.
The first CliniPrime product, the CliniPrime Fresh Leukopak, fulfills the industry need for ready access to cGMP-enabled, enriched leukocyte cellular starting materials. CliniPrime leverages Charles River’s established production processes to provide advanced therapy programs a high-quality product offering to support both clinical trial development and commercialization, while reducing client resource investment and risk.
With the CliniPrime portfolio Charles River now offers two options for GMP-compliant cellular starting material. CliniPrime products provide a standardized production process while GMPrime™ products enable clients to customize the production process of cellular starting material to meet specific needs for their program. Those two options for GMP-compliant starting material are also complemented by the HemaPrime portfolio of research use only (RUO) cellular products that include fresh leukopaks and other cellular products.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!